ECSP066575A - Antagonistas del receptor b1 de bradiquinina - Google Patents
Antagonistas del receptor b1 de bradiquininaInfo
- Publication number
- ECSP066575A ECSP066575A EC2006006575A ECSP066575A ECSP066575A EC SP066575 A ECSP066575 A EC SP066575A EC 2006006575 A EC2006006575 A EC 2006006575A EC SP066575 A ECSP066575 A EC SP066575A EC SP066575 A ECSP066575 A EC SP066575A
- Authority
- EC
- Ecuador
- Prior art keywords
- present
- bradiquinine
- peptides
- conjugated peptides
- biologically active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
Abstract
La presente invención se relaciona con ciertos péptidos biológicamente activos y péptidos conjugados que se pueden utilizar como terapéuticos o profilácticos contra enfermedades o condiciones ligadas a B1 como los agentes causantes. En una modalidad preferida de la invención los péptidos conjugados PEG biológicamente activos se suministran. En un aspecto de la presente invención, los péptidos conjugados PEG farmacológicamente activos de la presente invención son útiles para tratar la inflamación o dolor.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51391303P | 2003-10-22 | 2003-10-22 | |
US53892904P | 2004-01-24 | 2004-01-24 | |
US10/972,236 US7605120B2 (en) | 2003-10-22 | 2004-10-21 | Antagonists of the brandykinin B1 receptor |
PCT/US2004/034976 WO2005042027A2 (en) | 2003-10-22 | 2004-10-22 | Antagonists of the bradykinin b1 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066575A true ECSP066575A (es) | 2006-10-17 |
Family
ID=34990807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006575A ECSP066575A (es) | 2003-10-22 | 2006-05-18 | Antagonistas del receptor b1 de bradiquinina |
Country Status (15)
Country | Link |
---|---|
US (4) | US7605120B2 (es) |
EP (1) | EP1677830B1 (es) |
JP (1) | JP4896728B2 (es) |
KR (2) | KR100860654B1 (es) |
AU (1) | AU2004285467A1 (es) |
BR (1) | BRPI0415755A (es) |
CA (1) | CA2545499A1 (es) |
EA (1) | EA009294B1 (es) |
EC (1) | ECSP066575A (es) |
ES (1) | ES2395546T3 (es) |
IL (1) | IL175084A0 (es) |
MA (1) | MA28160A1 (es) |
NO (1) | NO20062198L (es) |
SG (1) | SG149872A1 (es) |
WO (1) | WO2005042027A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5036533B2 (ja) * | 2004-04-23 | 2012-09-26 | アムジエン・インコーポレーテツド | 持続放出製剤 |
EP1906929A2 (en) * | 2005-04-25 | 2008-04-09 | Amgen Inc. | Biodegradable peptide sustained release compositions containing porogens |
EP2574624A1 (en) | 2006-04-20 | 2013-04-03 | Amgen Inc. | GLP-1 compounds |
US7403325B2 (en) * | 2006-05-19 | 2008-07-22 | Xerox Corporation | Electrophoretic display device |
EP2738257A1 (en) | 2007-05-22 | 2014-06-04 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
WO2008153967A1 (en) * | 2007-06-08 | 2008-12-18 | Contec Therapeutics, Inc. | Bk1 antagonist conjugates |
US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
US20110118219A1 (en) * | 2008-03-25 | 2011-05-19 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
AR073997A1 (es) | 2008-10-29 | 2010-12-15 | Wyeth Corp | Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit |
AU2009314311B2 (en) | 2008-10-29 | 2013-01-10 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
WO2010091306A1 (en) | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
CA3018235C (en) | 2009-03-20 | 2021-01-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
WO2010110887A1 (en) * | 2009-03-24 | 2010-09-30 | Robert Shorr | Fatty acids |
CN108314733A (zh) * | 2010-07-16 | 2018-07-24 | 埃博灵克斯股份有限公司 | 修饰的单结构域抗原结合分子及其应用 |
WO2012040518A2 (en) | 2010-09-22 | 2012-03-29 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
DE102011118029A1 (de) | 2011-06-20 | 2012-12-20 | Universität Leipzig | Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung |
CN105682662A (zh) | 2013-03-14 | 2016-06-15 | 马里兰大学巴尔的摩校区 | 雄激素受体减量调节剂及其用途 |
WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
US11401303B2 (en) | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
CA3151034A1 (en) * | 2021-03-03 | 2022-09-03 | Kashiv Biosciences, Llc | Bioassay method for compounds useful to treat pain |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2435642A1 (de) | 1974-07-24 | 1976-02-05 | Hoffmann La Roche | Traegermaterial |
US4693993A (en) | 1985-06-13 | 1987-09-15 | Stewart John M | Bradykinin antagonist peptides |
US4801613A (en) | 1985-06-13 | 1989-01-31 | Nova Technology Limited Partnership | Bradykinin antagonist peptides |
US4923963A (en) | 1987-09-02 | 1990-05-08 | Nova Technology Limited Partnership | Bradykinin antagonist peptides |
EP0318162A3 (en) | 1987-11-25 | 1990-11-07 | Texaco Development Corporation | Novel bismaleimide derivatives |
US5648333A (en) | 1988-11-24 | 1997-07-15 | Hoechst Aktiengesellschaft | Peptides having bradykinin antagonist action |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5416191A (en) | 1991-04-01 | 1995-05-16 | Cortech, Inc. | Bradykinin antagonists |
US5863899A (en) | 1991-04-01 | 1999-01-26 | Cortech, Inc. | Bradykinin antagonists |
WO1992018156A1 (en) | 1991-04-19 | 1992-10-29 | Nova Technology Limited Partnership | Bradykinin antagonist peptides |
US6407207B1 (en) | 1992-03-30 | 2002-06-18 | Merck & Co., Inc. | Cloned and expressed human bradykinin BK-2 receptor |
US5521158A (en) | 1992-10-08 | 1996-05-28 | Scios Nova Inc. | Pseudopeptide bradykinin receptor antagonists |
US5541286A (en) | 1992-10-08 | 1996-07-30 | Scios Nova Inc. | Bradykinin antagonist pseudopeptide derivatives of olefinic aminoalkanoic acids |
US5955430A (en) * | 1993-09-24 | 1999-09-21 | University Of Southern California | Use of angiotensin II fragments and analogs thereof in tissue repair |
AU696429B2 (en) | 1994-03-09 | 1998-09-10 | Cortech, Inc. | Bradykinin antagonist peptides incorporating n-substituted glycines |
US5648336A (en) | 1994-11-18 | 1997-07-15 | University Of Colorado | Bradykinin antagonist peptides containing indane-substituted amino acids |
US5834431A (en) * | 1995-09-08 | 1998-11-10 | Cortech, Inc. | Des-Arg9 -BK antagonists |
US5849863A (en) | 1995-09-08 | 1998-12-15 | University Of Colorado | Cytolytic bradykinin antagonists |
AU3935897A (en) | 1996-08-19 | 1998-03-06 | Universite De Sherbrooke | B1-bradykinin receptor antagonists and use thereof |
JP3274076B2 (ja) | 1996-12-16 | 2002-04-15 | セイコーインスツルメンツ株式会社 | ペプチド断片を得る方法 |
US5935932A (en) | 1997-06-13 | 1999-08-10 | University Technology Corporation | Bradykinin antagonists containing pentafluorophenylalanine |
US6388054B1 (en) | 1998-08-20 | 2002-05-14 | John M. Stewart | Anti-cancer compounds |
US6875741B2 (en) * | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
AU2001238595A1 (en) * | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
CN100448891C (zh) * | 2001-05-11 | 2009-01-07 | 安姆根有限公司 | 与tall-1结合的肽和相关分子 |
US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
BR0315198A (pt) * | 2002-10-09 | 2005-08-30 | Insert Therapeutics Inc | Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos |
EP1603392A2 (en) * | 2003-03-07 | 2005-12-14 | The University Of Toledo | Paclitaxel hybrid derivatives |
-
2004
- 2004-10-21 US US10/972,236 patent/US7605120B2/en not_active Expired - Fee Related
- 2004-10-22 SG SG200900445-8A patent/SG149872A1/en unknown
- 2004-10-22 JP JP2006536809A patent/JP4896728B2/ja active Active
- 2004-10-22 ES ES04796039T patent/ES2395546T3/es active Active
- 2004-10-22 EA EA200600817A patent/EA009294B1/ru not_active IP Right Cessation
- 2004-10-22 EP EP04796039A patent/EP1677830B1/en active Active
- 2004-10-22 AU AU2004285467A patent/AU2004285467A1/en not_active Abandoned
- 2004-10-22 KR KR1020087002104A patent/KR100860654B1/ko not_active IP Right Cessation
- 2004-10-22 CA CA002545499A patent/CA2545499A1/en not_active Abandoned
- 2004-10-22 KR KR1020067009876A patent/KR20060105757A/ko active Search and Examination
- 2004-10-22 BR BRPI0415755-9A patent/BRPI0415755A/pt not_active IP Right Cessation
- 2004-10-22 WO PCT/US2004/034976 patent/WO2005042027A2/en active Application Filing
-
2006
- 2006-04-20 IL IL175084A patent/IL175084A0/en unknown
- 2006-05-12 MA MA29025A patent/MA28160A1/fr unknown
- 2006-05-15 NO NO20062198A patent/NO20062198L/no not_active Application Discontinuation
- 2006-05-18 EC EC2006006575A patent/ECSP066575A/es unknown
-
2008
- 2008-04-08 US US12/082,224 patent/US8288351B2/en not_active Expired - Fee Related
- 2008-04-08 US US12/082,219 patent/US8278280B2/en not_active Expired - Fee Related
- 2008-04-09 US US12/082,395 patent/US20090048149A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2545499A1 (en) | 2005-05-12 |
AU2004285467A1 (en) | 2005-05-12 |
EA009294B1 (ru) | 2007-12-28 |
EP1677830B1 (en) | 2012-10-17 |
KR20060105757A (ko) | 2006-10-11 |
EA200600817A1 (ru) | 2006-12-29 |
US7605120B2 (en) | 2009-10-20 |
SG149872A1 (en) | 2009-02-27 |
IL175084A0 (en) | 2006-08-20 |
EP1677830A2 (en) | 2006-07-12 |
WO2005042027A2 (en) | 2005-05-12 |
JP4896728B2 (ja) | 2012-03-14 |
NO20062198L (no) | 2006-07-18 |
KR20080015054A (ko) | 2008-02-15 |
US8278280B2 (en) | 2012-10-02 |
BRPI0415755A (pt) | 2006-12-19 |
WO2005042027A3 (en) | 2006-02-09 |
JP2007526240A (ja) | 2007-09-13 |
MA28160A1 (fr) | 2006-09-01 |
US8288351B2 (en) | 2012-10-16 |
US20050215470A1 (en) | 2005-09-29 |
AU2004285467A2 (en) | 2005-05-12 |
US20090048149A1 (en) | 2009-02-19 |
ES2395546T3 (es) | 2013-02-13 |
KR100860654B1 (ko) | 2008-09-26 |
US20090137452A1 (en) | 2009-05-28 |
US20090137483A1 (en) | 2009-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066575A (es) | Antagonistas del receptor b1 de bradiquinina | |
EA200601776A1 (ru) | Метадоновые композиции местного действия и способы их применения | |
AR048833A1 (es) | Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos | |
NI200500087A (es) | Derivados 4-tetrazolyl-4 fenilpiperidina para el tratamiento del dolor | |
CY1105082T1 (el) | Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας | |
ATE401874T1 (de) | Verabreichung von capsaicinoiden | |
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
HN2003000207A (es) | Moduladores del receptor de glucocorticoides | |
AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
CR8207A (es) | Un conjugado citotoxico ca6 antigeno- especifico y metodos para utilizar el mismo | |
HN2003000182A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodo para su uso | |
GT200100211A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos. | |
ECSP045217A (es) | Derivados de n-bifenilmetil aminocicloalcancarboxamida con un sustituyente en el metilo, util como antagonistas de bradicinina | |
AR023130A1 (es) | Composiciones para promover el crecimiento | |
HN2001000244A (es) | Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas. | |
ES2213707T3 (es) | Estimulacion del crecimiento oseo con un derivado peptidico de la trombina. | |
SE0002754D0 (sv) | New pharmaceutical combination formulation and method of treatment with the combination | |
ECSP045153A (es) | Metodo y composición para aumentar la potencia de un analgésico de narcotico. | |
AR065581A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
CY1112269T1 (el) | Συνθεσεις και μεθοδοι για την αγωγη, μειωση, βελτιωση, ή ανακουφιση των οφθαλμικων παθησεων οπισθιου- τμηματος | |
HN2003000080A (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
NI200300045A (es) | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. | |
ES2174337T3 (es) | Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular. | |
TR200103271T2 (tr) | İnflamasyon aracılığıyla gerçekleşen infeksiyon için anti-inflamatuar tedavi. | |
PE20050144A1 (es) | Composicion para mejorar funciones cognitivas y la memoria |